[
  {
    "ts": "2026-01-07T10:00:00+00:00",
    "headline": "Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical",
    "summary": "Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. “This collaboration with Ono Pharmaceutical represents another strong validation of our platform’s ability to uncover new disease biology and identify novel targets for rare and common indications,” said",
    "url": "https://finance.yahoo.com/news/scenic-biotech-enters-license-research-100000020.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0bf17e97-0ae1-3e1b-bdbe-c60d2c3d99fb",
      "content": {
        "id": "0bf17e97-0ae1-3e1b-bdbe-c60d2c3d99fb",
        "contentType": "STORY",
        "title": "Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical",
        "description": "",
        "summary": "Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. “This collaboration with Ono Pharmaceutical represents another strong validation of our platform’s ability to uncover new disease biology and identify novel targets for rare and common indications,” said",
        "pubDate": "2026-01-07T10:00:00Z",
        "displayTime": "2026-01-07T10:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/f3c92d6a92a356b689039c33cf879964",
          "originalWidth": 1200,
          "originalHeight": 434,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lAjiTNmRG0.Ss9XknecrMQ--~B/aD00MzQ7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f3c92d6a92a356b689039c33cf879964.cf.webp",
              "width": 1200,
              "height": 434,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D_peJ4xkwgcevfSdGfXIeQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f3c92d6a92a356b689039c33cf879964.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/scenic-biotech-enters-license-research-100000020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/scenic-biotech-enters-license-research-100000020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OPHLF"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ALNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T14:00:04+00:00",
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-140004056.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6b1a9cf0-6618-3619-9b6f-ff97d18d6b21",
      "content": {
        "id": "6b1a9cf0-6618-3619-9b6f-ff97d18d6b21",
        "contentType": "STORY",
        "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
        "description": "",
        "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
        "pubDate": "2026-01-07T14:00:04Z",
        "displayTime": "2026-01-07T14:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9.bMA28djqdXWkJ0xgkrvA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yGQaN1QLRXutAaqBqcTUKw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-140004056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-140004056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T16:35:49+00:00",
    "headline": "Should You Chase the Rally in Alumis Stock Today?",
    "summary": "Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.",
    "url": "https://www.barchart.com/story/news/36930672/should-you-chase-the-rally-in-alumis-stock-today",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "c3ce47a3-9bb9-3ca9-8a48-787e69dc48e9",
      "content": {
        "id": "c3ce47a3-9bb9-3ca9-8a48-787e69dc48e9",
        "contentType": "STORY",
        "title": "Should You Chase the Rally in Alumis Stock Today?",
        "description": "",
        "summary": "Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.",
        "pubDate": "2026-01-07T16:35:49Z",
        "displayTime": "2026-01-07T16:35:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/754d1add9645fb46c7ad31fc4fa63ccc",
          "originalWidth": 1600,
          "originalHeight": 1038,
          "caption": "Stock exchange financial or forex graph by Bigc Studio via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rVpZE7yOuMtu5ThdGK8Y5Q--~B/aD0xMDM4O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/754d1add9645fb46c7ad31fc4fa63ccc.cf.webp",
              "width": 1600,
              "height": 1038,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6diRt2JefKs07rA2CWiSdQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/754d1add9645fb46c7ad31fc4fa63ccc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36930672/should-you-chase-the-rally-in-alumis-stock-today",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chase-rally-alumis-stock-today-163549709.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALMS"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T21:20:00+00:00",
    "headline": "3 Drug Stocks to Buy at a Discount",
    "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
    "url": "https://www.fool.com/investing/2026/01/07/3-drug-stocks-to-buy-at-a-discount/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ceb8fea2-15df-3ba3-9ab5-45ae1d883b70",
      "content": {
        "id": "ceb8fea2-15df-3ba3-9ab5-45ae1d883b70",
        "contentType": "STORY",
        "title": "3 Drug Stocks to Buy at a Discount",
        "description": "",
        "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
        "pubDate": "2026-01-07T21:20:00Z",
        "displayTime": "2026-01-07T21:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4f71bf990154afb24c7a9a05250a0185",
          "originalWidth": 1369,
          "originalHeight": 800,
          "caption": "A finger flipping dice that spell out long term and short term.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A02CqIBRKDDimBJfuetC5Q--~B/aD04MDA7dz0xMzY5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4f71bf990154afb24c7a9a05250a0185.cf.webp",
              "width": 1369,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Nz1FKdFVpAkt9roiVdww2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4f71bf990154afb24c7a9a05250a0185.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/07/3-drug-stocks-to-buy-at-a-discount/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-drug-stocks-buy-discount-212000896.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T22:13:20+00:00",
    "headline": "Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks",
    "summary": "If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks through the key numbers that matter for value focused investors. The share price recently closed at US$54.42, with returns of 0.4% over 7 days, 4.4% over 30 days, 1.8% year to date, 0.1% over 1 year, negative 12.9% over 3 years and 1.4% over 5 years. Taken together, these figures present a mixed picture for anyone thinking about long term value. Recent headlines around...",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-pricing-221320020.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "461a0abf-f88e-3835-a00a-75d3332fdf9a",
      "content": {
        "id": "461a0abf-f88e-3835-a00a-75d3332fdf9a",
        "contentType": "STORY",
        "title": "Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks",
        "description": "",
        "summary": "If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks through the key numbers that matter for value focused investors. The share price recently closed at US$54.42, with returns of 0.4% over 7 days, 4.4% over 30 days, 1.8% year to date, 0.1% over 1 year, negative 12.9% over 3 years and 1.4% over 5 years. Taken together, these figures present a mixed picture for anyone thinking about long term value. Recent headlines around...",
        "pubDate": "2026-01-07T22:13:20Z",
        "displayTime": "2026-01-07T22:13:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-pricing-221320020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-pricing-221320020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T23:10:21+00:00",
    "headline": "Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves",
    "summary": "Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how recent price moves and mixed growth metrics might fit into a broader long term thesis. See our latest analysis for Bristol-Myers Squibb. The recent 1 day share price return of 4.23% builds on short term momentum, with a 30 day share price return of 9.77% and a 90 day gain of 26.95%, while the 3 year total shareholder return of 9.60% decline shows that longer term holders...",
    "url": "https://finance.yahoo.com/news/assessing-bristol-myers-squibb-bmy-231021073.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "35225d93-1548-3288-9e84-06cebe71f260",
      "content": {
        "id": "35225d93-1548-3288-9e84-06cebe71f260",
        "contentType": "STORY",
        "title": "Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves",
        "description": "",
        "summary": "Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how recent price moves and mixed growth metrics might fit into a broader long term thesis. See our latest analysis for Bristol-Myers Squibb. The recent 1 day share price return of 4.23% builds on short term momentum, with a 30 day share price return of 9.77% and a 90 day gain of 26.95%, while the 3 year total shareholder return of 9.60% decline shows that longer term holders...",
        "pubDate": "2026-01-07T23:10:21Z",
        "displayTime": "2026-01-07T23:10:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-bristol-myers-squibb-bmy-231021073.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-bristol-myers-squibb-bmy-231021073.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]